[HT-05-5] Biogen Perspective on Drug Development for Neurological Diseases The example of Alzheimers Disease
神経系創薬は抗体医薬と核酸医薬のバイオ医薬による分子標的治療が実現し、新しい世代に入った。その一方でアルツハイマー病の抗体医薬の治験は第Ⅲ相での失敗が続き、神経系創薬は未だに困難な側面を内包している。 欧米ではオープンイノベーションによる創薬は50％を超え、アカデミア発のシーズから革新的バイオ医薬が実現している。日本においても急速に産学連携の創薬研究に進捗がみられるが、その一方で、日本のアカデミア発のシーズが創薬に結び付く成功確率が低いという現実がある。本シンポジウムでは、アカデミア発創薬の産官学連携の現状と展望に加えて、大手製薬会社の神経系研究開発の責任者にそれぞれの考える今後の神経系創薬の方向性について話を聞きたい。（企画：将来構想委員会）
Alfred W. Sandrock Jr. is the Executive Vice President, Research and Development and Chief Medical Officer at Biogen, Inc. Dr. Sandrock has served as Chief Medical Officer since November 2015 and was recently named Head of R&D in October 2019. Since joining Biogen in 1998, Dr. Sandrock has held several senior executive positions including Group Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Prior to joining Biogen, Dr. Sandrock was Assistant Professor of Neurology at Harvard Medical School and an Assistant in Neurology at Massachusetts General Hospital.
Dr. Sandrock received a B.A. in Human Biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in Neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in neuromuscular disease and clinical neurophysiology (electromyography) at Massachusetts General Hospital in Boston, MA.
Dr. Sandrock is also a Director at Neurocrine Biosciences, Inc, Praxis Precision Medicines, Inc., and Disarm Therapeutics Inc., and is a member of the Partners Healthcare Innovation Advisory Board. He serves as Chairman of the Board of the PhRMA Foundation.
抄録パスワード認証
パスワードは抄録集に記載してあります。